This application for renewal of the UW/FHCRC CFAR includes the University of Washington, Fred Hutchinson Cancer Research Center, Seattle BioMed, and Seattle Children's Hospital, Foundation and Research Institute, and international partner institutions. Our CFAR has over 560 faculty, pre- and postdoctoral trainees, and research scientists. Matching financial support for our CFAR from partner institutions equals 35% of CFAR Direct Costs. The highly interdisciplinary CFAR membership represents 12 of the 16 UW Schools and Colleges and all five FHCRC Divisions. Annual external HIV/AIDS research, training, and service program funding to our four CFAR partners currently exceeds $362 million, including $160 million for 148 awards from six of seven CFAR co-sponsoring NIH institutes, OAR and the Fogarty Center. This warrants effective coordination and communication by the CFAR to optimize the return on investment. Strategic research priorities for the future are (1) Prevent New HIV Infections;(2) Improve HIV Disease Outcomes;(3) Expand Basic Science Discovery Research;and (4) Reduce HIV-Related Health Disparities. To achieve these aims, our goals are (1) Develop a New Generation of Young Innovative HIV/AIDS Researchers;and (2) Provide infrastructure, resources, and incentives for Sustainable Interdisciplinary Translational Science. Ten proposed Cores (three new or completely restructured) and three new Scientific Working Groups (SWGs) emphasize (1) Clinical, Epidemiology, Health Services, and Health Economics Research;(2) Socio- Behavioral and Prevention Research;and (3) Basic Discovery Research, including Retrovirology, Immunology, and Molecular Profiling/Computational Biology. Each Core has individual-level and population-level components, domestic and international components, and collaborations within and external to our CFAR. For the twenty-sixth year of the UW/FHCRC CFAR, we will continue to be innovative. A multi-stage Strategic planning process led to: (1) Merging current Clinical Research and Clinical Retrovirology Cores to improve efficiency and reduce costs;(2) Replacing the Computational Biology Core with a new Molecular Profiling and Computational Biology Core that synergizes FHCRC and UW strengths;(3) Creating an AIDS-Associated Infections and Malignancies Core from a successful SWG;and (4) Launching three new SWGs to build upon strong UW/FHCRC programs for research on Substance Abuse and HIV/STI;Implementation Science;and Curative Therapies for HIV. Cross-CFAR Cores (Administration, Developmental, Biometrics, and International) will support and interact with every Core. The CFAR will support and provide added value for future local, national and international HIV/AIDS research priorities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-27
Application #
8646839
Study Section
Special Emphasis Panel (ZAI1-UKS-A (J1))
Program Officer
Namkung, Ann S
Project Start
1997-03-01
Project End
2018-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
27
Fiscal Year
2014
Total Cost
$3,448,438
Indirect Cost
$857,615
Name
University of Washington
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Stekler, Joanne D; McKernan, Jennifer; Milne, Ross et al. (2015) Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther 20:77-80
Mohanraj, Rani; Jeyaseelan, Visalakshi; Kumar, Shuba et al. (2015) Cultural adaptation of the Brief COPE for persons living with HIV/AIDS in southern India. AIDS Behav 19:341-51
Mackelprang, Romel D; Bigham, Abigail W; Celum, Connie et al. (2014) Toll-like receptor polymorphism associations with HIV-1 outcomes among sub-Saharan Africans. J Infect Dis 209:1623-7
Gantt, Soren; Cattamanchi, Ashok; Krantz, Elizabeth et al. (2014) Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol 60:127-32
Slyker, Jennifer A; Casper, Corey; Tapia, Kenneth et al. (2014) Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy. Clin Infect Dis 58:1333-7
Gerdts, Sarah E; Wagenaar, Bradley H; Micek, Mark A et al. (2014) Linkage to HIV care and antiretroviral therapy by HIV testing service type in Central Mozambique: a retrospective cohort study. J Acquir Immune Defic Syndr 66:e37-44
Liu, Yi; Rao, Ushnal; McClure, Jan et al. (2014) Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds. PLoS One 9:e94240
Puttkammer, Nancy H; Zeliadt, Steven B; Balan, Jean Gabriel et al. (2014) Before and after the earthquake: a case study of attrition from the HIV antiretroviral therapy program in Haiti. Glob Health Action 7:24572
Pantalone, David W; Huh, David; Nelson, Kimberly M et al. (2014) Prospective predictors of unprotected anal intercourse among HIV-seropositive men who have sex with men initiating antiretroviral therapy. AIDS Behav 18:78-87
Wagner, Thor A; McLaughlin, Sherry; Garg, Kavita et al. (2014) HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345:570-3

Showing the most recent 10 out of 552 publications